New research has resulted in a new potential therapeutic option for vascular endothelial growth factor (VEGF) after being demonstrated on a mouse model. The results are being presented during the 2021 Annual Meeting of The Association for Research in Vision and Ophthalmology (ARVO), being hosted virtually this year.
Preliminary research suggests possible application of manipulated gut bacteria may have therapeutic implications in treating age-related macular degeneration (AMD). The early model system is being presented at the 2021 Annual Meeting of The Association for Research in Vision and Ophthalmology (ARVO), being hosted virtually this year.
A study being presented at the virtual 2021 Annual Meeting of The Association for Research in Vision and Ophthalmology (ARVO) clarifies and further confirms the relationship between optic nerve cupping and glaucoma using unsupervised artificial intelligence (AI) techniques, unveiling component patterns.
A new study being presented at the virtual 2021 Annual Meeting of The Association for Research in Vision and Ophthalmology (ARVO) points to the cause of high incidence of sleep disorders in patients with glaucoma.
New research out of the University of Delaware has identified age- and sex-dependent changes in gene expression, highlighting differences between how male and female lenses age. The results will be presented at the virtual 2021 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO).
New research being presented at the virtual 2021 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) demonstrates a novel refillable implant dubbed the Port Delivery System with ranibizumab (PDS) can continuously release the anti-VEGF drug ranibizumab—a proven therapy—into the eye(s) of patients with neovascular age-related macular degeneration (nAMD). PDS is currently an investigational therapy being developed by Genentech, a member of the Roche Group, and is not yet approved by the U.S. Food and Drug Administration
The Association for Research in Vision and Ophthalmology (ARVO) today announced the recipient of the Pfizer Ophthalmics Carl Camras Translational Research Award. The award, funded by Pfizer Ophthalmics through the ARVO Foundation, honors Dr. Carl Camras, who is highly respected for his work as a glaucoma specialist and a research scientist, by annually awarding up to three $12,000 awards to young investigators working in areas of translational research. The 2021 awardee is Alex Huang, MD, PhD of the Doheny Eye Institute and University of California in Los Angeles.
The Association for Research in Vision and Ophthalmology (ARVO) today announced the recipient of the Mallinckrodt Uveitis Research Fellowship, generously funded by Mallinckrodt Pharmaceuticals. The award, funded through the ARVO Foundation, supports an early career investigator with a one-year grant of $45,000 to study an aspect of uveitis or other inflammatory conditions of the eye. The 2021 awardee is Shilpa Kodati, MD of the National Eye Institute (NEI) at the National Institutes of Health (NIH).
The Association for Research in Vision and Ophthalmology (ARVO) today announced the 2021 recipients of the Dr. David L. Epstein Award. Jamie Craig, MBBS, FRANZCO, DPhil and Owen Siggs, MD, DPhil, are the recipients of the $100,000 award which is funded through the ARVO Foundation.
The Association for Research in Vision and Ophthalmology (ARVO) today announced the 2021 recipients of the Roche Collaborative Research Fellowships. Wanjiku Mathenge MBChB, MMed, MSc, PhD, Sudhir H Ranganath, PhD, and Pablo Federico Barcelona, PhD, are the recipients of the fellowships that are generously funded by F. Hoffmann-La Roche Ltd., through the ARVO Foundation.
The Association for Research in Vision and Ophthalmology (ARVO) today announced the recipients of the Lewis Rudin Glaucoma Prize. The award, funded by the May and Samuel Rudin Family Foundation with support of his brother Jack Rudin via the ARVO Foundation, provides a $30,000 award in recognition of an outstanding scholarly article on glaucoma published in a peer-reviewed journal during the previous calendar year. The 2020 recipients are Iqbal Ahmad Ph.D. and Pooja Teotia, PhD, of the University of Nebraska in Omaha, Neb.
The Association for Research in Vision and Ophthalmology (ARVO) announced today the recipients of the 2021 Genentech Age-Related Macular Degeneration (AMD) Research Fellowships. The two recipients will each receive $40,000 to support research focused on an aspect of AMD. The 2021 recipients are Yi-Rong Peng, PhD and Kevin J. McHugh, PhD.
The Association for Research in Vision and Ophthalmology (ARVO) today announced Yohei Tomita, MD, PhD, has received the 2021 Bert M. Glaser, MD Award for Innovative Research in Retina, which recognizes an early-career investigator who has made a novel discovery that impacted the understanding and/or treatment of a retinal disease or condition. Tomita is recognized with this award for his retinal translational research, with a focus on diabetic retinopathy (DR) and age-related macular degeneration (AMD).
The Association for Research in Vision and Ophthalmology (ARVO) announced today the recipient of the inaugural 2021 Genentech Career Development Award for Underrepresented Minority (URM) Emerging Vision Scientists. The early-career URM investigator recipient will receive a two-year grant totaling $100,000 to promote the generation of promising preliminary research results. The 2021 recipient is Elizabeth Zuniga-Sanchez, PhD of Baylor College of Medicine in Houston, Texas.
The Association for Research in Vision and Ophthalmology (ARVO) announced today the recipients of the inaugural 2020 Advocacy Awards. The recipient of the Achievements in Eye and Vision Advocacy Award is João M. Furtado, MD, PhD of the Ribeirão Preto Medical School, University of São Paulo. The recipient of the Emerging Advocate Award is Jarrod C. Harman of Louisiana State University Health Sciences Center (LSUHSC).
The Association for Research in Vision and Ophthalmology (ARVO) and ARVO Foundation for Eye Research announce the opening of nominations for their respective awards, including three new awards— the Genentech Career Development Award for Underrepresented Minority Emerging Vision Scientists, the Achievements in Eye and Vision Advocacy Award, and the Emerging Advocate Award—on July 1, 2020.
On July 8, the Alliance for Eye and Vision Research (AEVR) in conjunction with the Tear Film & Ocular Surface Society (TFOS) will host the Fifth Annual Dry Eye Awareness Month Congressional Briefing entitled How Lifestyle Changes During the COVID-19 Pandemic Can Affect Vision.
The Association for Research in Vision and Ophthalmology (ARVO) today announced the launch of a new career development program aimed to provide early-career underrepresented minority (URM) scientists the opportunity to explore novel and innovative ideas through a two-year $100,000 grant.
The Association for Research in Vision and Ophthalmology (ARVO) and the Eye Bank Association of America (EBAA) today announced a new grant program that will provide financial support to researchers seeking to use human eye tissue in their work.
New research suggests that adding 30 minutes of daily outdoor activity reduces the progression of nearsightedness, called myopia, in children if the activity is continued. The study, conducted by researchers in Beijing, China, is published in the May 2019 issue of Translational Vision Science & Technology (TVST).
Dry eye disease is a global problem affecting more than 30 million people in the United States alone. The Alliance for Eye and Vision Research, in conjunction with Tear Film & Ocular Surface Society, will hold a Congressional Briefing and Screening entitled Ongoing Impact of TFOS DEWS II™ on Dry Eye Clinical Practice & Research, on Capitol Hill, July 10. The Briefing features a panel of experts who participated in the development of the Report speaking about its impact on clinical practice and research.
The Association for Research in Vision and Ophthalmology (ARVO) today announced the launch of a new fellowship for early-career researchers. The Mallinckrodt Uveitis Research Fellowship, generously funded by Mallinckrodt Pharmaceuticals, will support early career investigators with a one-year grant of $45,000 in their endeavor to investigate the impetus of uveitis or other inflammatory conditions in innovative ways.
Thanks to technology discovered through federally funded research, doctors are helping babies born early see better. Cynthia A. Toth, MD of Duke Eye Center will join other vision experts and researchers from around the country at the 2018 Focus on Eye Health National Summit to share the story of the technology used in neonatal intensive care units (NICU) around the country.
The world’s leading ocular oncology scientists and clinicians are meeting this summer to discuss the latest research and treatment developments in eye cancer. The Ocular Oncogenesis and Oncology Conference (OOO) will be held by the Association for Research in Vision and Ophthalmology (ARV0) in partnership with the Champalimaud Foundation, July 18 – 21 at the Champalimaud Centre for the Unknown in Lisbon, Portugal
Steven J. Fliesler, PhD, FARVO, of the State University of New York-Buffalo and VA Western NY Healthcare System-Buffalo is the new president of the Association for Research in Vision and Ophthalmology (ARVO). He succeeds Claude F. Burgoyne, MD, FARVO, (Devers Eye Institute) whose one-year term ended in May following the ARVO Annual Meeting.
A recent study shows that a new eye drop may be a potentially effective treatment for seasonal eye allergies, a condition affecting millions of people worldwide. The findings will be presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Honolulu, Hawaii, Sunday, April 29 – Thursday, May 3
The findings of two new studies may help advance the diagnosis and treatment of eye cancers. The research is being presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Honolulu, Hawaii, Sunday, April 29 – Thursday, May 3.
Two new research studies demonstrate that imaging technologies can help to diagnose and detect the progression of glaucoma, one of the leading causes of blindness in the U.S. When diagnosed early, vision loss from glaucoma can be slowed or prevented. The two studies are being presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Honolulu, Hawaii, Sunday, April 29 – Thursday, May 3.
Researchers from around the world are sharing the latest high-tech advances in research to treat, diagnose and prevent diseases causing vision loss. The new findings demonstrate the impact of technology on vision and on vision science. The five studies will be presented in a news conference — virtually and onsite — at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Honolulu, Hawaii, on Tuesday, May 1 at 9am.
In a new study, vision researchers found that certain types of lightbulbs and reading at different times of the day may contribute to nearsightedness, a condition clinically referred to as myopia. In another study, scientists found that a common food flavoring may offer new treatment options for reducing nearsightedness. The findings from the three new studies are being presented at the Association for Research in Vision and Ophthalmology (ARVO) in Honolulu, Hawaii, Sunday, April 29 – Thursday, May 3.
Three new studies demonstrate research findings that could offer novel treatments for vision and eye conditions. The studies will be presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Honolulu, Hawaii, from Sunday, April 29 – Thursday, May 3.
Two new studies demonstrate potential future opportunities to use genetic information to treat vision conditions. The new studies are being presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Honolulu, Hawaii, Sunday, April 29 – Thursday, May 3.
The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting is the largest gathering of eye and vision researchers in the world, with over 11,000 attendees from more than 75 countries. The five-day meeting will feature more than 6,000 poster and paper presentations of cutting-edge eye and vision research, offering an early glimpse into the latest advances in potential treatments for eye disease and blindness — often years ahead of their introduction to clinical practice.
The most recent basic and clinical research developments related to the diagnosis and treatment of eye cancer will be the focus of a scientific meeting convened by the Association for Research in Vision and Ophthalmology (ARV0) in partnership with the Champalimaud Foundation. The Ocular Oncogenesis and Oncology Conference will be held July 18 – 21 at the Champalimaud Centre for the Unknown, a state-of-the-art medical and research facility located in Lisbon, Portugal
Leading vision scientists from the U.S. and around the world will gather in Washington, DC on Feb. 9 to discuss federal research funding with members of Congress. The researchers will share examples of how investing taxpayer dollars into basic science has resulted in cost savings for patients and for the Medicare program overall.
A new study quantifying a 21-fold return on investment suggests an efficient — and non-partisan — method to cut healthcare spending is to invest in basic research. The paper tracks how a new technology aids doctors in reducing the number of unnecessary drug injections used to treat a blinding condition called wet age-related macular degeneration (AMD)
In a study well-timed for summer, vision scientists have found that eye freckles, dark spots on the colored part of the eye (iris), are more frequently found in people with higher lifetime exposure to sunlight. While not malignant, eye freckles could indicate the presence or risk of sunlight-triggered eye diseases like cataract or macular degeneration.
Three years after an Ebola epidemic swept across West Africa, researchers have found a clue to how the virus may live on in the eyes of survivors suffering from uveitis – one of the more serious and common complications of the disease.
A new, personalized and noninvasive treatment using 3-D printed implants has been developed to help children born with abnormally small or missing eyes (microphthalmia/ anophthalmia, or MICA). The research is being presented at the 2017 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Baltimore, Md.
A generic glaucoma drug has been shown to halt the progression of myopia (nearsightedness), potentially offering rapid approval for a new treatment of an incurable condition. The research is being presented at the 2017 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Baltimore, Md.
Scientists have developed a new method to clear antibiotic resistant bacteria from the surface of the eye – introducing a new strain of bacteria that preys on other microorganisms. The research is being presented at the 2017 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Baltimore, Md.
A survey of adult participants seen in an urban eye hospital revealed that one-in-five study participants had clinically significant depressive symptoms. The research is being presented at the 2017 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Baltimore, Md.
Scientists have demonstrated the capacity to grow specialized neurons that relay visual data to the brain, creating a source of cells for future treatments of glaucoma and other optic neurodegenerative diseases. The research is being presented during a press conference at the 2017 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Baltimore, Md., on Monday, May 8 from 9:30 – 10:15am.
Using augmented-reality (AR) display systems, scientists have restored visual function in the amblyopic (lazy) eyes of patients outside of the currently accepted window for treatment. The research is being presented at the 2017 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Baltimore, Md.
Surgeons have successfully used a remote controlled robotic system to operate inside the human eye, paving the way for future robotic assistance in clinical treatments that require extreme precision and stability, such as the controlled delivery of gene therapy and stem cells. The research is being presented at the 2017 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Baltimore, Md.
Scientists have demonstrated that a machine learning algorithm, using images of patients’ retinas obtained over time, can predict the critical moment when early or intermediate age-related macular degeneration (AMD) will progress into severe AMD. The research is being presented during a press conference at the 2017 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Baltimore, Md, on Monday, May 8 from 9:30 – 10:15 am.
Scientists have shown for the first time that gestational exposure to marijuana smoke in animals affects the development of the eye and these alterations seem to progress with age. The research is being presented during a press conference at the 2017 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Baltimore, Md., on Monday, May 8 from 9:30 – 10:15am.
Over 11,000 top eye and vision researchers and clinicians from around the world will attend the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), May 7-11, in Baltimore, Md., to explore cutting-edge findings in basic and clinical science. The theme and focus of this year's agenda is on creating stronger global connections and effective collaborations to accelerate vision research.
For the first time, information about worldwide blindness and vision impairment is being projected onto NASA’s room-sized, global display system during the Annual Meeting of the Association for Research in Vision and Ophthalmology (May 7 – 11 at the Baltimore Convention Center).
Three researchers at the ARVO 2017 Annual Meeting will share their latest results, including: Who will get AMD? Teaching algorithms to predict who’s at risk; Restoring vision: New hope for retinal cell replacement, and Prenatal marijuana use: Potential long-term effects on babies’ eyes.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right